Clinical trial combo LEE011 and MEK162

Posted By
1/11/2014 3:14pm
View other posts by
Activity
Replies: 2

Hello all.  Anyone out there have information of this trial offered at Vanderbilt and MSK?   I have appointment next week in New York.  Have been researching this as well as their trial using attenuated dendrite cells as a vaccine to be used intradermally.  I am stage 3 B and refused the interferon arm of interferon vs ipi in my local area.  Any info appreciated re both therapies would be appreciated.  Lucy3

Sounds very promising.  Hoping it prevnts the resistaance of the other BRAF tagets to arise.

http://www.medindia.net/news/new-drug-proves-effective-in-drug-resistant...
In many cancers, a tumor suppressor protein called retinoblastoma is deactivated because of an increase in the activity of the proteins CDK 4 and 6. This results in unchecked cell proliferation. The activity of CDK4/6 is regulated by cyclin D, whose expression is increased by activation of BRAF and PIK3CA, which are implicated in some melanomas and breast cancers, respectively. Drugs targeting BRAF and PIK3CA have had success, but most treated cancers subsequently develop resistance to these drugs.

"Chemistry optimization has led to the discovery of LEE011, which, to our knowledge, is the most selective CDK4/6 inhibitor to date," said William Sellers, M.D., vice president and global head of oncology at the Novartis Institutes for Biomedical Research in Cambridge, Mass. "Utilizing the latest cancer genomics data and our knowledge of the role of CDK4/6 activity in the growth of tumor cells, we have identified unique indications and combinations of drugs with LEE011, in which LEE011 demonstrates a robust antitumor activity.

"One of the most notable findings is that, when paired with other targeted agents, LEE011 is often able to prevent the emergence of resistance to the partner compound that would otherwise arise when the partner compound is dosed alone."

Based on the results from preclinical experiments, Novartis has initiated multiple phase I trials in adult cancers, and a phase I trial in pediatric cancers is ongoing. "Preliminary data show LEE011 is well tolerated with excellent pharmacokinetic properties," said Sellers. Combination studies of LEE011 and other Novartis pipeline drugs are underway, according to him.

Sellers and colleagues conducted preliminary studies using cancer cells in culture and found that LEE011 inhibited the growth of tumor cells primarily by arresting the cells at a "checkpoint" called G1, which prevents the cell from multiplying. Further in vivo experiments showed that because cyclin D1 is a target of BRAF and PIK3CA, LEE011 was effective as a single agent in mice bearing melanomas with BRAF mutations, and those bearing breast cancers with PIK3CA mutations.

When tested in combination with an investigational BRAF inhibitor, LGX818, in melanoma, LEE011 showed robust antitumor activity in mice sensitive or resistant to LGX818. Similarly, when combined with an investigational PIK3CA inhibitor, BYL719, LEE011 showed significant antitumor activity in mice bearing breast cancers sensitive or resistant to BYL719.

In the phase I clinical trial in adult patients, the investigators are testing LEE011 as a single agent in cancers that are dependent on CDK4/6, including liposarcomas, mantle cell lymphomas, and head and neck cancers. In the ongoing phase I study on pediatric cancers, LEE011 is being tested as a single agent in neuroblastoma and malignant rhabdoid tumors.

"CDK4/6 inhibition offers a new strategy to directly attack the uncontrolled growth that defines cancer. LEE011 is a new and highly selective CDK4/6 inhibitor that Novartis hopes will be of clinical benefit, and we are progressing to patients as quickly as possible," said Sellers.

I'm me, not a statistic. Praying to not be one for years yet.

Anonymous - (1/12/2014 - 7:56pm)

Hi Lucy, do you know your Braf/Nras status? There are two two different trials:

http://clinicaltrials.gov/show/NCT01781572 for Nras melanoma, which is MEK + LEE

http://clinicaltrials.gov/show/NCT01543698 for Braf melanoma, which is MEK + LEE + Tafinlar